SCHEMBL3843536

SCHEMBL3843536

N#Cc1ccc2cccnc2c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.53
MEN1 O00255 1/20 0.53
CASP1 P29466 1/20 0.53
CASP7 P55210 1/20 0.53
KMT2A Q03164 1/20 0.53
CYP1A2 P05177 1/20 0.53
CYP2C19 P33261 1/20 0.53
HTT P42858 1/20 0.53
NR4A2 P43354 1/20 0.53
CYP17A1 P05093 1/20 0.46
CYP11B1 P15538 1/20 0.46
CYP11B2 P19099 1/20 0.46
CLK4 Q9HAZ1 1/20 0.46
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
METAP2 P50579 1/20 0.44
METAP1 P53582 1/20 0.44
SLC40A1 Q9NP59 1/20 0.44
CYP3A4 P08684 1/20 0.42
NPC1 O15118 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27793193 0.98 ALDH1A1 (0.52) ALDH1A1MEN1CASP1CASP7KMT2A
Hydrochloric Acid SCHEMBL28325576 0.98 ALDH1A1 (0.52) ALDH1A1MEN1CASP1CASP7KMT2A
Quinoline SCHEMBL28240764 0.95 ALDH1A1 (0.59) ALDH1A1MEN1CASP1CASP7KMT2A
Isoquinoline SCHEMBL28860064 0.86 CYP11B2 (0.47) ALDH1A1MEN1CASP1CASP7KMT2A
SCHEMBL31588535 0.85 POLB (0.57) ALDH1A1MEN1CASP1KMT2AHTT
SCHEMBL29843637 0.85 POLB (0.57) ALDH1A1MEN1CASP1KMT2AHTT
SCHEMBL506632 0.85 POLB (0.57) ALDH1A1MEN1CASP1KMT2AHTT
Quinoline SCHEMBL28269682 0.84 ALDH1A1 (0.59) ALDH1A1MEN1CASP1KMT2AHTT
Fluoride SCHEMBL28218511 0.83 POLB (0.55) ALDH1A1MEN1CASP1KMT2AHTT
SCHEMBL28153180 0.83 POLB (0.55) ALDH1A1MEN1CASP1KMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110382475-A NRF2 activator 比奥根MA公司 2019-10-25 CN claimed
US-10224485-B2 Process for preparing a crystalline organic semiconductor material BASF SE (DE) 2019-03-05 US claimed
CN-105025899-B Having a2AHeterobicyclically substituted- [1,2,4 ] antagonists]Triazolo [1,5-c]Quinazoline-5-amine compounds 默沙东公司 2017-08-18 CN claimed
CN-103717597-B Heterocyclic compounds as kinase inhibitors 原真股份有限公司 2017-07-04 CN claimed
CN-106458994-A Biaryl kinase inhibitors 百时美施贵宝公司 2017-02-22 CN claimed
US-20170012208-A1 ORGANIC SEMICONDUCTOR FORMULATIONS USINVEST LLC 2017-01-12 US claimed
CN-104837490-A Pyrimido [4,5-b ] quinoline-4, 5(3H,10H) -diones as nonsense mutation suppressors NOVARTIS AG 2015-08-12 CN claimed
EP-2699572-A1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS Origenis GmbH (DE) 2014-02-26 EP claimed
WO-2012143143-A1 HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS ORIGENIS GMBH (DE) 2012-10-26 WO claimed
CN-1934116-B Tricyclic benzopyran compounds useful as antiarrhythmic agents NISSAN CHEMICAL IND LTD 2012-10-10 CN claimed
CN-101429200-A Tricyclic benzopyran compound as anti-arrhythmic agents NISSAN CHEMICAL IND LTD (JP) 2009-05-13 CN claimed
CN-100432055-C Tricyclic protein kinase inhibitors WYETH CORP (US) 2008-11-12 CN claimed
CN-1934116-A Tricyclic benzopyran compounds useful as antiarrhythmic agents NISSAN CHEMICAL IND LTD (JP) 2007-03-21 CN claimed
CN-1704404-A Tricyclic protein kinase inhibitors WYETH CORP (US) 2005-12-07 CN claimed
CN-1121391-C Substituted 3-cyano quinolines AMERICAN CYANAMID CO (US) 2003-09-17 CN claimed
CN-1437584-A Tricyclic protein kinase inhibitors WYETH CORP (US) 2003-08-20 CN claimed
CN-1429126-A Use of cyanoquinolines for treating or inhibiting colonic polyps AMERICAN CYANAMID CO (US) 2003-07-09 CN claimed
EP-1242382-A1 TRICYCLIC PROTEIN KINASE INHIBITORS Wyeth (US) 2002-09-25 EP claimed
WO-2001047892-A1 TRICYCLIC PROTEIN KINASE INHIBITORS WYETH (US) 2001-07-05 WO claimed
CN-1259125-A Substituted 3-cyanoquinolines AMERICAN CYANAMID CO (US) 2000-07-05 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10224485-B2 Process for preparing a crystalline organic semiconductor material STOM, SPOP, TTR ALDH1A1 4757/4885MEN1 722/4885CASP1 2309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.